Article citationsMore>>

F. L. Luan, L. J. Stuckey, J. M. Park, D. Kaul, D. Cibrik and A. Ojo, “Six-Month Prophylaxis Is Cost Effective in Transplant Patients at High Risk for Cytomegalovirus Infection,” Journal of American Society of Nephrology, Vol. 20, No. 11, 2009, pp. 2449-2458. doi:10.1681/ASN.2008111166

has been cited by the following article:

• TITLE: A Case of Cytomegalovirus-Induced Arthritis after Lymphocyte-Depleting Therapy for Kidney Allograft Rejection

  AUTHORS: Richard Fuquay, James Eric Cooper

  KEYWORDS: Cytomegalovirus (Mesh); Arthritis (Mesh); Kidney Transplantation (Mesh); Immunosuppression (Mesh); Chemoprevention (Mesh); Valganciclovir (Mesh)

  JOURNAL NAME: Open Journal of Nephrology, Vol.2 No.1, March 28, 2012

  ABSTRACT: Cytomegalovirus viremia and tissue-invasive disease are common after kidney transplantation. Chemoprophylaxis has made substantial improvement in this clinical problem. Here we report a 29-year-old woman who had kidney allograft rejection and received lymphocyte-depleting therapy. She presented with a new oligo-arthritis that led to 2 successive arthrocenteses. The etiology of the inflammation could not be determined initially. On the second arthrocentesis, a synovial fluid cytomegalovirus polymerase chain reaction test was positive. The patient responded to treatment with valganciclovir, had negative follow-up serum cytomegalovirus polymerase chain reaction tests, and experienced resolution of her joint inflammation. We review briefly the data for cytomegalovirus chemoprophylaxis, preemptive screening, and treatment recommendations.